Table I.

Patient, Disease and Transplant Characteristics

	Total Population	Other PTCL	CTCL)
Characteristic	N (%) or Median (Range)	N (%) or Median (Range)	N (%) or Median (Range)
Number of patients (N)	37	24	13
Patient Gender
Male	27	18	9
Female	10	6	4
Age at Transplant (years)	40 (7–72)	39.5 (7–72)	50 (18–61)
Donor Type
Sibling	26 (70.3)	19 (79.2)	7 (53.8)
Matched Unrelated Donor	11 (29.7)	5 (20.8)	6 (46.2)
Disease Status at Transplant
1st Complete Remission	3	2	1
2nd Complete Remission	4	4	0
Partial Remission	5	5	0
1st Relapse	7	5	2
Primary Progressive	1	0	1
Primary Induction Failure	17 (46.0)	8	9
PIT Groups
1 (PIT Score = 0)	NA	13 (54.2)	NA
2 (PIT Score = 1)	NA	2 (8.3)	NA
3 (PIT Score = 2)	NA	6 (25.0)	NA
Unknown	NA	3 (12.5)	NA
Prior Regimens	3 (1–9)	3 (1–8)	6 (4–9)
Months from Diagnosis to Transplant	17 (4–112)	11 (4–112)	38 (9–88)
Stem Cell Source
Bone Marrow	5 (13.5)	4 (16.7)	1 (7.7)
Peripheral Blood	31 (83.8)	19 (79.2)	12 (92.3)
Cord Blood	1 (2.7)	1 (4.2)	0
Conditioning Intensity
Reduced	22 (59.4)	13 (54.2)	9 (69.2)
Non-myeloablative	2 (5.4)	1 (4.2)	1 (7.7)
Myeloablative	13 (35.1)	10 (41.7)	3 (23.1)
Conditioning Regimen
Bu | Cy	1	0	1
FTBI | Cy	7	5	2
FTBI | Cy | ATG	1	1	0
FTBI | VP-16	4	4	0
Fludarabine | TBI	2	1	1
Fludarabine | Melphalan	22 (59.5)	13	9
GVHD Prophylaxis
CSA/MMF Based	20 (54.1)	12 (50.0)	8 (61.5)
Tacro/Siro Based	17 (45.9)	12 (50.0)	5 (38.5)

MF–mycosis fungoides, SS–Sézary Syndrome, CTCL–cutaneous T-cell lymphoma, DX–diagnosis, Bu–busulfan, CTX–cyclophosphamide, FTBI–fractionated total body irradiation, ATG–anti-thymocyte globulin, VP-16–etoposide, CSA–cyclosporine, MMF–mycophenylate mofetil